Latest Conference Articles

December 12th 2019, 10:31pm

SABCS

Nearly 65% of patients whose disease had spread to lymph nodes showed no signs of cancer following a regimen of Keytruda plus chemotherapy compared with those who received chemotherapy alone.

December 12th 2019, 1:21am

SABCS

Results from a phase 3 trial showed significant increases in five-year invasive disease-free survival estimates among Japanese patients with hormone receptor-positive, HER2-negative breast cancer.

December 12th 2019, 12:24am

SABCS

Researchers found that the addition of Perjeta to Herceptin plus chemotherapy reduced the relative risk for breast cancer recurrence or death in patients with operable HER2-positive early breast cancer, according to a six-year follow-up.

December 11th 2019, 10:05pm

SABCS

The HER2-targeted antibody-drug conjugate T-DXd achieved a response in 60.9% of patients, according to phase 2 study findings.

December 11th 2019, 3:00am

American Society of Hematology Annual Meeting

Expanding a combination from two drugs to three may lengthen the time until disease progression for patients with relapsed or refractory multiple myeloma.

December 11th 2019, 1:00am

American Society of Hematology Annual Meeting

Patients aged 55 and over remained in remission after receiving CC-486, according to phase 3 study findings.

December 10th 2019, 11:00pm

American Society of Hematology Annual Meeting

Whole genome sequencing of blood and bone marrow from patients with acute myeloid leukemia and myelodysplastic syndrome has revealed previously unknown disease subtypes.

December 10th 2019, 7:00pm

American Society of Hematology Annual Meeting

In a phase 3 clinical trial, Blincyto (blinatumomab), a type of immunotherapy, improved survival and showed fewer side effects in young patients.

December 10th 2019, 1:00am

American Society of Hematology Annual Meeting

Results presented at ASH 2019 suggest the combination therapy is superior to chemoimmunotherapy.

December 8th 2019, 11:00pm

American Society of Hematology Annual Meeting

New findings show that the socioeconomic status of children with AML plays a significant and alarming roll in the rate of their overall survival after diagnosis.

December 8th 2019, 9:00pm

American Society of Hematology Annual Meeting

Baseline laboratory values for AML clinical trials are setting unnecessary restrictions for kidney function that excludes African American patients with AML when this comorbidity does not impact overall survival.

December 8th 2019, 6:00pm

American Society of Hematology Annual Meeting

Some patients with non-Hodgkin lymphoma may soon have a treatment option that could offer complete remission, according to new data presented at the American Society of Hematology 2019 Annual Meeting.

December 8th 2019, 1:18am

American Society of Hematology Annual Meeting

A dual-targeted chimeric antigen receptor-T cell therapy showed a more than 90% overall response rate in patients with relapsed or refractory disease.

December 7th 2019, 10:36pm

American Society of Hematology Annual Meeting

JNJ-4528 showed deep responses and proved to be safe in patients with multiple myeloma, according to CARTITUDE-1 study findings.

October 21st 2019, 10:00pm

A Vision of Hope: A Kidney Cancer Educational Symposium

Dr. Camillo Porta discussed what is new in kidney cancer beyond the first line of treatment at A Vision of Hope: A Kidney Cancer Educational Symposium.

October 17th 2019, 1:00am

A Vision of Hope: A Kidney Cancer Educational Symposium

Those with non-clear cell kidney cancer have much to look forward to as oncologists’ understanding of the disease is evolving.

October 16th 2019, 1:00am

A Vision of Hope: A Kidney Cancer Educational Symposium

Pre- and post-surgical treatment could benefit patients with kidney cancer who are at high risk for disease recurrence.

October 14th 2019, 5:00pm

A Vision of Hope: A Kidney Cancer Educational Symposium

One patient advocate explained how patients with renal cell carcinoma can query about clinical trials and what they need to know about them to do so.

October 12th 2019, 10:00pm

A Vision of Hope: A Kidney Cancer Educational Symposium

Nutrition plays a key role in kidney cancer; however, the need to address it is still unmet.

October 12th 2019, 12:03am

A Vision of Hope: A Kidney Cancer Educational Symposium

One expert explained what patients should know about their kidney cancer diagnosis at A Vision of Hope: A Kidney Cancer Educational Symposium.

October 2nd 2019, 1:00am

ESMO

“Survivors living with recurrent breast cancer have unique needs and programs that address these needs can enhance patient satisfaction,” the study authors wrote.

September 30th 2019, 5:49pm

ESMO

Two studies showed that adding a CDK4/6 inhibitor to treatment with Faslodex improved survival among women with hormone receptor-positive, human epidermal growth factor2-negative advanced breast cancer.

September 30th 2019, 12:00am

ESMO

First-line Tagrisso significantly extended overall survival compared with first generation EGFR-TKIs in patients with Ex19del/L858R EGFR mutated advanced non–small cell lung cancer, according to results from the phase 3 FLAURA study.

September 29th 2019, 10:00pm

ESMO

One in two patients with metastatic melanoma is alive five years following treatment with Opdivo plus Yervoy, according to long-term follow-up of the phase 3 CheckMate 067 trial.

September 29th 2019, 6:00pm

ESMO

Frontline maintenance therapy with Zejula lengthened time without disease progression among women with newly diagnosed, advanced ovarian cancer, according to findings from the phase 3 PRIMA study.

September 29th 2019, 1:00am

ESMO

First-line treatment with Opdivo plus low-dose Yervoy improved survival among patients with advanced NSCLC compared to chemotherapy, according to results from the CheckMate-227 trial.

September 28th 2019, 11:18pm

ESMO

The addition of Lynparza to maintenance therapy with Avastin improved time to disease progression in women with advanced ovarian cancer, according results of the PAOLA-1/ENGOT-ov25 trial.

September 28th 2019, 6:43pm

ESMO

Morever, the next-generation androgen receptor improved overall survival, compared with placebo, in patients with nonmetastatic castration-resistant prostate cancer, according to updated findings of the phase 3 SPARTAN trial.

August 5th 2019, 9:19pm

ASCO Annual Meeting

The executive director of the Cancer Policy Institute at the Cancer Support Community offers some candid advice for individuals who may be facing a new cancer diagnosis.

July 29th 2019, 6:05pm

ASCO Annual Meeting

The merging of MyLifeLine.org with Cancer Support Community facilitates more comprehensive social and emotional support for patients and caregivers affected by cancer.